1-50 of 73
Keywords: Alzheimer's disease
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Biochem Soc Trans (2023) 51 (1): 173–182.
Published: 23 January 2023
...Heather M. Wilkins Mitochondrial dysfunction and Aβ accumulation are hallmarks of Alzheimer's disease (AD). Decades of research describe a relationship between mitochondrial function and Aβ production. Amyloid precursor protein (APP), of which Aβ is generated from, is found within mitochondria...
Articles
Biochem Soc Trans (2023) 51 (1): 147–159.
Published: 11 January 2023
...Rima Budvytyte; Gintaras Valincius Misfolding, aggregation and accumulation of Amyloid-β peptides (Aβ) in neuronal tissue and extracellular matrix are hallmark features of Alzheimer's disease (AD) pathology. Soluble Aβ oligomers are involved in neuronal toxicity by interacting with the lipid...
Articles
Articles
Articles
Biochem Soc Trans (2016) 44 (1): 185–190.
Published: 09 February 2016
... precursor protein (APP), the central molecule in Alzheimer's disease aetiology, as a novel interaction partner of a subunit of the PIKfyve complex, Vac14. Furthermore, it has been shown that APP modulates PIKfyve function and PI(3,5) P 2 dynamics, suggesting that the APP gene family functions as regulator...
Articles
Biochem Soc Trans (2015) 43 (5): 920–923.
Published: 09 October 2015
...Hongyun Li; Tim Karl; Brett Garner ATP-binding cassette transporter A7 (ABCA7) is highly expressed in the brain. Recent genome-wide association studies (GWAS) identify ABCA7 single nt polymorphisms (SNPs) that increase Alzheimer's disease (AD) risk. It is now important to understand the true...
Articles
Articles
Biochem Soc Trans (2014) 42 (5): 1321–1325.
Published: 18 September 2014
...Emma C. Phillips; Cara L. Croft; Ksenia Kurbatskaya; Michael J. O’Neill; Michael L. Hutton; Diane P. Hanger; Claire J. Garwood; Wendy Noble Increased production of amyloid β-peptide (Aβ) and altered processing of tau in Alzheimer's disease (AD) are associated with synaptic dysfunction, neuronal...
Articles
Biochem Soc Trans (2014) 42 (5): 1316–1320.
Published: 18 September 2014
...Amy M. Birch Astrocytes were historically classified as supporting cells; however, it is becoming increasingly clear that they actively contribute to neuronal functioning under normal and pathological conditions. As interest in the contribution of neuroinflammation to Alzheimer's disease (AD...
Articles
Biochem Soc Trans (2014) 42 (5): 1291–1301.
Published: 18 September 2014
... 2014 Biochemical Society 2014 Alzheimer’s disease amyotrophic lateral sclerosis glia Huntington’s disease neurodegeneration Parkinson’s disease At the later stages of ALS, reactive astrogliosis also comes to the fore, as well as the activation of microglial cells [ 53 , 58...
Articles
Biochem Soc Trans (2014) 42 (4): 1001–1005.
Published: 11 August 2014
...Irundika H.K. Dias; Maria C. Polidori; Helen R. Griffiths Blood cholesterol levels are not consistently elevated in subjects with age-related cognitive decline, although epidemiological studies suggest that Alzheimer's disease and cardiovascular diseases share common risk factors. These include...
Articles
Articles
Biochem Soc Trans (2013) 41 (6): 1583–1587.
Published: 20 November 2013
... with Alzheimer's disease, the most common age-related dementia associated with impairments in learning and memory accompanied by neuroinflammation, oxidative stress and neurodegeneration. The present mini-review examines the evidence supporting the roles that ECs appear to play in Alzheimer's disease...
Articles
Biochem Soc Trans (2013) 41 (6): 1495–1502.
Published: 20 November 2013
...MaryKate McBrayer; Ralph A. Nixon Early-onset FAD (familial Alzheimer's disease) is caused by mutations of PS1 (presenilin 1), PS2 (presenilin 2) and APP (amyloid precursor protein). Beyond the effects of PS1 mutations on proteolytic functions of the γ-secretase complex, mutant or deficient PS1...
Articles
Biochem Soc Trans (2013) 41 (5): 1331–1334.
Published: 23 September 2013
...Carola Stockburger; Christopher Kurz; Konrad A. Koch; Schamim H. Eckert; Kristina Leuner; Walter E. Müller The metabolic enhancer piracetam is used in many countries to treat cognitive impairment in aging, brain injuries, as well as dementia such as AD (Alzheimer's disease). As a specific feature...
Articles
Biochem Soc Trans (2012) 40 (4): 681–686.
Published: 20 July 2012
...Norbert Zilka; Branislav Kovacech; Peter Barath; Eva Kontsekova; Michal Novák Pathological truncations of human brain proteins represent the common feature of many neurodegenerative disorders including AD (Alzheimer's disease), Parkinson's disease and Huntington's disease. Protein truncations...
Articles
Biochem Soc Trans (2012) 40 (4): 693–697.
Published: 20 July 2012
... by Amritpal Mudher (Southampton, U.K.) and Makis Skoulakis (BSRC Alexander Fleming, Greece). Aβ amyloid β-peptide AD Alzheimer's disease FTDP-17 frontotemporal dementia with parkinsonism linked to chromosome 17 GTO granular tau oligomer HSP70 heat-shock protein 70 MT...
Articles
Biochem Soc Trans (2012) 40 (4): 641–643.
Published: 20 July 2012
...Efthimios M.C. Skoulakis; Amritpal Mudher It is an exciting time for tau researchers as it is now generally accepted that abnormal tau species are required to mediate the toxic effects of amyloid β-peptide oligomers in Alzheimer's disease. Tau may play multiple roles in neurophysiology...
Articles
Biochem Soc Trans (2012) 40 (4): 661–666.
Published: 20 July 2012
...Kurt R. Brunden; Carlo Ballatore; Virginia M.-Y. Lee; Amos B. Smith, III; John Q. Trojanowski Neurons within the brains of those with AD (Alzheimer's disease) and related neurodegenerative disorders, collectively termed ‘tauopathies’, contain fibrillar inclusions composed of hyperphosphorylated tau...
Articles
Articles
Biochem Soc Trans (2012) 40 (4): 698–703.
Published: 20 July 2012
... Correspondence may be addressed to either of these authors (email Guy.Lippens@univ-lille1.fr or Isabelle.Landrieu@univ-lille1.fr ). 28 2 2012 © The Authors Journal compilation © 2012 Biochemical Society 2012 AD Alzheimer's disease CDK cyclin-dependent kinase FRET fluorescence...
Articles
Biochem Soc Trans (2012) 40 (4): 677–680.
Published: 20 July 2012
... with parkinsonism linked to chromosome 17), affect alternative splicing of exon 10, encoding a microtubule-binding motif. Advanced RNA analysis methods have suggested that levels of exon 10-containing MAPT mRNA are elevated in Alzheimer's disease. Furthermore, the MAPT H1 haplotype, associated with Alzheimer's...
Articles
Biochem Soc Trans (2012) 40 (2): 297–309.
Published: 21 March 2012
... dysregulation of Ca 2+ signals have been linked to some of the major diseases in humans such as cardiac disease, schizophrenia, bipolar disorder and Alzheimer's disease. Ca 2+ pumps and exchangers are responsible for pumping Ca 2+ out of the cell or back into the ER. These pumps and exchangers operate...
Articles
Biochem Soc Trans (2012) 40 (1): 282–286.
Published: 19 January 2012
... the roles that they may play in neural processes, including differentiation, memory formation, circadian rhythm regulation, neurotransmitter/hormone release and the pathogenesis of neurodegenerative disorders associated with aberrant Ca 2+ signalling, such as Alzheimer's disease. 1 To whom...
Articles
Biochem Soc Trans (2011) 39 (4): 910–916.
Published: 20 July 2011
...Rita J. Guerreiro; John Hardy In the present review, we look back at the recent history of GWAS (genome-wide association studies) in AD (Alzheimer's disease) and integrate the major findings with current knowledge of biological processes and pathways. These topics are essential for the development...
Articles
Biochem Soc Trans (2011) 39 (4): 933–938.
Published: 20 July 2011
...Jonathan Gilley; Robert Adalbert; Michael P. Coleman Considering the many differences between mice and humans, it is perhaps surprising how well mice model late-onset human neurodegenerative disease. Models of Alzheimer's disease, frontotemporal dementia, Parkinson's disease and Huntington's...
Articles
Biochem Soc Trans (2011) 39 (4): 851–856.
Published: 20 July 2011
...Lindsay Graham; Calum Sutherland The analysis of the molecular development of AD (Alzheimer's disease) is technically challenging, due to the chronic nature of the disease, the lack of early and definitive clinical diagnosis, and the fact that the abnormal molecular pathology occurs in the brain...
Articles
Biochem Soc Trans (2011) 39 (4): 920–923.
Published: 20 July 2011
... and the formation of amyloid plaques is the central process in the development of the symptoms of Alzheimer's disease. However, most clinical trials in this area have been disappointing; therefore the attendees of the Models of Dementia: the Good, the Bad and the Future meeting were given the opportunity to openly...
Articles
Biochem Soc Trans (2011) 39 (4): 886–890.
Published: 20 July 2011
...Hannah Johnston; Herve Boutin; Stuart M. Allan Inflammation has long been proposed as having a role in AD (Alzheimer's disease), although it remains unclear whether inflammation represents a cause or consequence of AD. Evidence from the clinical setting in support of a role for inflammation in AD...
Articles
Articles
Biochem Soc Trans (2010) 38 (6): 1474–1478.
Published: 24 November 2010
...Katrijn Coen; Wim Annaert AD (Alzheimer's disease) is a neurodegenerative disease characterized by a gradual loss of neurons and the accumulation of neurotoxic Aβ (amyloid β-peptide) and hyperphosphorylated tau. The discovery of mutations in three genes, PSEN1 (presenilin 1), PSEN2 (presenilin 2...
Articles
Biochem Soc Trans (2010) 38 (4): 1012–1015.
Published: 26 July 2010
... it is possible that the hyperphosphoryation of tau may contribute to the pathogenesis of Alzheimer's disease by promoting the formation of neurofibrillary tangles from cytosolic tau, and also by inhibiting additional tau functions through disruption of its targeting to the plasma membrane. 1 To whom...
Articles
Biochem Soc Trans (2010) 38 (4): 1001–1005.
Published: 26 July 2010
... (Alzheimer's disease)-like NFTs (neurofibrillary tangles) in an age-dependent manner. Since murine tau might interfere with the toxic effects of human mutant tau, we set out to analyse the phenotype of our Tg30tau model in the absence of endogenous murine tau with the aim to reproduce more faithfully a model...
Articles
Articles
Biochem Soc Trans (2010) 38 (4): 981–987.
Published: 26 July 2010
.... Bombois S. Blum D. Delacourte A. Pasquier F. Vanmechelen E. Biochemistry of Tau in Alzheimer's disease and related neurological disorders Expert Rev. Proteomics 2008 5 207 224 6 Delacourte A. Tauopathies: recent insights into old diseases Folia Neuropathol. 2005...
Articles
Articles
Biochem Soc Trans (2010) 38 (4): 988–992.
Published: 26 July 2010
...Catherine M. Cowan; David Shepherd; Amritpal Mudher AD (Alzheimer's disease) is a neurodegenerative disorder characterized by the abnormal hyperphosphorylation and aggregation of the microtubule-associated protein tau and the misfolding and deposition of Aβ peptide. The mechanisms by which tau...
Articles
Biochem Soc Trans (2010) 38 (4): 993–995.
Published: 26 July 2010
...Frank M. LaFerla Aβ (amyloid β-peptide) and tau are the main proteins that misfold and accumulate in amyloid plaques and NFTs (neurofibrillary tangles) of Alzheimer's disease and other neurological disorders. Historically, because plaques and NFTs accumulate in diverse cellular compartments, i.e...
Articles
Biochem Soc Trans (2010) 38 (4): 953–954.
Published: 26 July 2010
... in the pathology of the various behaviourally and neuropathologically distinct tauopathies, the mechanisms of tau toxicity and the potential functional interaction of tau and amyloid in Alzheimer's disease remain elusive. Nevertheless, novel observations regarding the various aspects of taumisregulation-dependent...
Articles
Biochem Soc Trans (2010) 38 (4): 973–976.
Published: 26 July 2010
... aggregates [ 32 ]. The aggresome–autophagy system represents the next line of protection against accumulation of these protein aggregates [ 24 ]. Protein aggregation is a common pathological hallmark of many neurological disorders. In a subset of these diseases, including AD (Alzheimer's disease...
Articles
Biochem Soc Trans (2010) 38 (4): 996–1000.
Published: 26 July 2010
...Jean-Pierre Brion; Kunie Ando; Céline Heraud; Karelle Leroy NFTs (neurofibrillary tangles) in Alzheimer's disease and in tauopathies are hallmark neuropathological lesions whose relationship with neuronal dysfunction, neuronal death and with other lesions [such as Aβ (amyloid β-peptide) pathology...
Articles
Biochem Soc Trans (2010) 38 (4): 955–961.
Published: 26 July 2010
...Yipeng Wang; Sarika Garg; Eva-Maria Mandelkow; Eckhard Mandelkow Tau aggregation is a hallmark of several neurodegenerative diseases, including AD (Alzheimer's disease), although the mechanism underlying tau aggregation remains unclear. Recent studies show that the proteolysis of tau plays...
Articles
Articles
Biochem Soc Trans (2010) 38 (2): 466–470.
Published: 22 March 2010
...–42 have provided encouraging candidates for AD (Alzheimer's disease) medicines in animal models, although none have yet proved to be effective in human trials. We have been investigating approaches to treat systemic amyloidoses, conditions that show common features with some CNS (central nervous...
Articles
Biochem Soc Trans (2010) 38 (2): 545–551.
Published: 22 March 2010
...Ayodeji A. Asuni; V. Hugh Perry; Vincent O'Connor Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied...
Articles
Biochem Soc Trans (2010) 38 (2): 564–570.
Published: 22 March 2010
...Catherine M. Cowan; Francis Chee; David Shepherd; Amritpal Mudher Axonal microtubules are essential for transport of materials to the synapse. Compromised microtubules and synaptic loss have been demonstrated in AD (Alzheimer's disease), which is believed to contribute to cognitive dysfunction...
Articles
Biochem Soc Trans (2009) 37 (5): 1126–1132.
Published: 21 September 2009
... proposed in cancer, Alzheimer's disease and HIV treatment. These numerous therapeutic roles elevate VPA to near ‘panacea’ level. Surprisingly, the mechanisms of action of VPA in the treatment of many of these disorders remain unclear, although it has been shown to alter a wide variety of signalling...
Articles
Biochem Soc Trans (2009) 37 (4): 692–696.
Published: 22 July 2009
...Hozefa Amijee; Jill Madine; David A. Middleton; Andrew J. Doig The aggregation of numerous peptides or proteins has been linked to the onset of disease, including Aβ (amyloid β-peptide) in AD (Alzheimer's disease), asyn (α-synuclein) in Parkinson's disease and amylin in Type 2 diabetes. Diverse...
Articles
Biochem Soc Trans (2008) 36 (6): 1299–1303.
Published: 19 November 2008
... be addressed (email bssdrb@bath.ac.uk ). 25 4 2008 © The Authors Journal compilation © 2008 Biochemical Society 2008 Alzheimer's disease amyloid precursor protein neurodegeneration Parkinson's disease prion synuclein transmissible spongiform encephalopathy (TSE) As metal...
Articles